Organization
Pharmacokinetics, Dynamics and Metabolism
1 abstract
Abstract
Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Institut Bergonié, Aix Marseille University - Assistance Publique Hopitaux De Marseille, Université Paris Saclay,